Axsome Therapeutics Inc. (AXSM)
104.56
0.09 (0.09%)
At close: Apr 17, 2025, 3:59 PM
104.28
-0.28%
After-hours: Apr 17, 2025, 06:51 PM EDT
0.09% (1D)
| Bid | 96 |
| Market Cap | 5.1B |
| Revenue (ttm) | 385.69M |
| Net Income (ttm) | -287.22M |
| EPS (ttm) | -5.99 |
| PE Ratio (ttm) | -17.46 |
| Forward PE | 43.03 |
| Analyst | Buy |
| Ask | 106 |
| Volume | 259,440 |
| Avg. Volume (20D) | 983,306.1 |
| Open | 105.19 |
| Previous Close | 104.47 |
| Day's Range | 103.92 - 105.62 |
| 52-Week Range | 64.11 - 139.13 |
| Beta | 0.88 |
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial ...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2015
Employees 683
Stock Exchange NASDAQ
Ticker Symbol AXSM
Website https://www.axsome.com
Analyst Forecast
According to 15 analyst ratings, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is $167, which is an increase of 59.71% from the latest price.
Stock ForecastsNext Earnings Release
Axsome Therapeutics Inc. is scheduled to release its earnings on May 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
-4.25%
Axsome Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
2 months ago
+4.03%
Axsome Therapeutics shares are trading higher after Mizuho raised its price target on the stock from $137 to $195 and B of A Securities raised its target from $143 to $167.
